A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...

Vimseltinib is now an FDA-approved treatment for patients with tenosynovial giant cell tumor, based on findings from the ...

Acute and chronic treatment for hepatic encephalopathy acquired from Mallinckrodt Pharmaceuticals in September 2024Extended pre-clinical, ...

Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced an update ...

The supplement industry is booming—but so are serious health issues tied to taking these pills and powders. Here’s what ...

Impact and progress Frontiers' impact Progress Report 2022 All progress reports ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...

Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its ...

A new, generic, non-steroidal anti-inflammatory drug (NSAID) is now available for managing osteoarthritis (OA) pain in horses ...

Weight gain medications—like some steroid-, cannabis-, and hormone-based prescriptions or supplements—may promote weight gain. Some chronic illnesses, surgery, and trauma to the body can lead ...

Hepatic fibrosis is a reversible wound healing response characterized by accumulation of extracellular matrix (ECM), or "scar," that follows chronic but not self-limited liver disease. The ECM ...

More than 36 million Americans have type 2 diabetes, a condition primarily attributed to the body's cells not responding to ...